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Pre-mRNA processing, referred to as alternative RNA splicing (AS), is a critical determinant of protein diversity (1, 2) . AS produces multiple transcripts and, as a result, multiple proteins from a single gene. Pre-mRNA splicing is executed in the nucleus by spliceosomes (1, 3, 4) . The efficiency of this process is controlled by classical trans-and cis-splicing elements (2, 5, 6) . Most studies of AS in AML patients have focused on individual genes, including AML1, Gfi1b, CD96, survivin-2B, AML-ETO and GSK3beta (7) (8) (9) (10) (11) (12) (13) . Studies that report splice variants of these genes also document the role of some of these variants in disease biology, while others can be used as prognostic or diagnostic biomarkers (13) (14) (15) (16) (17) (18) (19) (20) . Recently, frequent splicing machinery pathway mutations in myelodysplasia (MDS), AML and chronic lymphocytic leukemia (CLL) were identified (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) . Despite novel discoveries, genome-wide AS has not been extensively examined in patients with AML.
In present study, we evaluated genome-wide AS events in patients with AML. AS was found to be a common event for AML involving many genes in AML patients. Genome-wide, we found of the annotated genes (P<0.05). Some of these aberrant splicing events are highly recurrent in patients and affect genes encoding many oncogenes and tumor suppressor genes, or genes involved in regulation of apoptosis, the cell cycle, and cell differentiation. Overall, our study identifies widespread splicing abnormalities in AML, which points to a disruption in the mechanisms regulating in the splicing process. In the future, determining the underlying causes and consequences of aberrant splicing in AML could enhance our understanding of disease pathogenesis. Certain of the more common aberrant splice variants may generate new targets for the development of novel therapeutics for AML.
Materials and methods
Study design and patient cohort. This study includes a total of 228 samples from patients with AML; 193 samples were obtained from patients who were recruited at the DFCI (Dana-Farber Cancer Institute, USA) and 35 patients recruited at the UHN (the Hospital de Nantes, France)).
From these samples, 66 were analyzed on the Affymetrix Human Exon 1.0ST Arrays (31 from DFCI and 35 from UHN). Of the 228 samples 193 were used in validation studies and 29 in longitudinal study. All patient samples were taken at diagnosis after approval from the Institutional Review Boards, with written informed consent. Supplementary Tables S1 describes demographic, clinical and molecular characteristics of the AML patients that were included in the exon array analysis; patient records were reviewed retrospectively to verify diagnosis and status. A control group of 12 NDs of both genders were also included: 8 BM samples of NDs were obtained from AllCells (California) and 4 PB samples were obtained from healthy volunteers at the DFCI.
Research. Tissue and cell preparation. All samples from patients and NDs were purified using FicollHypaque gradient centrifugation. PB mononuclear cells and/or BM cells obtained from AML patients were enriched using the EasySep Human Progenitor Cell Enrichment Kit, which is designed to isolate hematopoietic progenitor cells by negative selection (Stem Cell Technologies).
From ND BM samples, CD34+ cells were obtained using the EasySep Human CD34 Positive Selection Kit (Stem Cell Technologies). After cell selection the presence of CD34+CD38-and CD34+CD38+, cell populations were evaluated by flow cytometry, which is routinely done in our laboratory.
Monocytes and neutrophils were isolated from four PB samples obtained from healthy volunteers using the EasySep Human Monocyte or Neutrophil Enrichment Kits (Stem Cell Technologies).
Cells were resuspended in RLT lysis buffer or in Trizol followed by the total RNA isolation procedure using an AllPrep RNA/DNA Isolation Kit (Qiagen) or Trizol (Life Technologies) reagent according to the manufacturer's recommendations. Patient samples included in the longitudinal studies were not enriched.
Microarray Hybridization. Prior to the Affymetrix GeneChip Whole Transcript Sense Target
Labeling assay, total RNA samples were evaluated on the 2100 Bioanalyzer (Agilent) using the RNA 6000 Nano Kit (Agilent). Subsequently, samples were hybridized to the Affymetrix Human Exon 1.0ST Arrays. All procedures were carried out at the DFCI Microarray core facility according to the recommended protocols. Hybridized arrays were scanned on an Affymetrix GeneChip Scanner 3000 and visually inspected for hybridization artifacts. The Affymetrix GeneChip Human Exon 1.0 ST array was used to identify global changes in splicing profiles associated with AML. Two independent AML cohorts were studied, which included the DFCI cohort of 31 patients and the UHN cohort of 35 patients, for a total of 66 samples. No significant differences were found between these two cohorts with respect to any common clinical characteristics other than hemoglobin levels (Supplementary Table S1a ).
Splicing events associated with the DFCI patient cohort
We compared splicing events in the DFCI cohort with those detected in NDs. After normalization and filtering procedures, using XRay software, 101,792 probes identifying 7,771 transcripts were scored as having above-background expression levels in the DFCI cohort, or in NDs. This analysis identified 29% (2,251 of 7,771) transcripts differentially spliced in patients compared to NDs, with a significance expression level of nominal P<0.05.
Next, we performed annotation analysis through NetAffx Analysis Center (affymetrix.com) to identify transcriptome regions of the DFCI cohort that were affected by aberrant splicing. This analysis showed that the 2,251 differentially spliced transcripts detected in the DFCI cohort correspond to 8,648 probe-sets. Of these, 6,573 (76%) mapped to known translated regions of the genome, 1,785 (21%) mapped to untranslated regions (introns, 5'UTRs or 3'UTRs) and 290 (3%) mapped to partial transcripts/cDNAs (Table 1) .
Using Ingenuity software, we identified gene categories affected by aberrant splicing in the DFCI cohort. We determined that 2,201 of the 2,251 differentially spliced transcripts mapped to the annotated genes in public databases. Mapped genes were categorized based on their location as well as the functions of proteins they encode. Of the differentially spliced genes, 41% encoded cytoplasmic proteins, 31% encoded nuclear proteins and 11% encoded plasma membrane proteins.
Results of these analyses are reported in Supplementary Table S2 .
Splicing events associated with the UHN patient cohort
To ensure that the genome-wide splicing profiles identified in the DFCI cohort were reproducible, we used a "biological repeats" approach for the exon array analyses. We performed identical exon array experiments for the independent UHN cohort. In this sample-set, 91,673 probes corresponding to 7,212 transcripts were expressed above background in patients or NDs. As in the DFCI cohort, 28% (2,004 of 7,212) of the UHN cohort transcripts were differentially spliced in patients compared to NDs at a significance level of nominal P<0.05. Next, we identified regions of the UHN cohort genome affected by the aberrant splicing. The differentially spliced transcripts in the UHN cohort correspond to 10,932 probe-sets, of which 8,794 (80%) mapped to translated regions, 1,842 (17%) mapped to untranslated regions such as introns, 5'UTRs or 3'UTRs, and 296 (3%) mapped to partial transcripts/cDNAs (Table 1) .
We categorized differentially spliced transcripts in the UHN cohort and found that 41% of the significantly spliced genes encoded cytoplasmic proteins, 30% encoded nuclear proteins, and 13% encoded plasma membrane proteins. These fractions are similar to those noted in the DFCI sample set. In both cohorts, annotation analyses indicated similar proportions of differentially spliced genes encoding enzymes, kinases, transcriptional and translational regulators or transporter proteins, splicing factors, heterogeneous nuclear ribonucleoproteins, and proteins involved in spliceosome assembly (Supplementary Table S2a ). Table   2 ). On average, we detected 350 genes (range 135-786) differentially spliced in the DFCI cohort as compared to NDs, while an average of 506 genes were differentially spliced in the UHN cohort. We also determined the frequency of each spliced gene in individual patients of these two cohorts. In the DFCI cohort each gene was spliced on average in 14 patients (range 1-29), while in the UHN cohort each gene was spliced on average in 18 patients (range 1-34) (Figure 1a-b, Table 2 ).
We identified 47% (1,062 of 2,251) transcripts in the DFCI cohort and 46% (922 of 2,004) transcripts in the UHN cohort that had been previously reported as alternatively spliced in AML or other tumors and other cellular systems ( Table 2) . We identified 53% (1,189 of 2,251) novel aberrant splice variant transcripts in the DFCI cohort and 54% (1,082 of 2,004) in the UHN cohort that are not reported. Furthermore, these lists include novel splice variants of 52 oncogenes (e.g., RUNX1, PML, AKT1, ARAF, BRAF, FOS, JUN) and 50 tumor suppressor genes (e.g., ATM, P53, FLT3, HDAC2, STK3, SYK), or genes that regulate cellular processes involved in the maintenance of homeostasis (Supplementary Table S2b ). These analyses show that genes mapping to certain chromosomes are more frequently spliced in AML patients than in NDs. Distribution of these aberrant splicing events genome-wide is shown in Figure 1a- Among the large number of aberrantly spliced genes, we have identified some of known splice variants that are associated with AML or other cancers, e.g. splice variants of RUNX1, MLL and CD96 previously reported as spliced in AML, a Syk variant in breast cancer, an FGFR1 variant in breast and brain cancers, a caspase-8 in T-cell leukemia, and CD44 and MDM2 splice variants reported in many different types of cancers.
We evaluated the extent of similarities between the DFCI and UHN patient cohorts with respect to splicing event frequency, and found that 75% (262 of 348) of the transcripts that were recurrently spliced in 30% or more of DFCI patient cohort were also recurrently spliced in the UHN patient cohort (Figure 1c, Supplementary Table S2c ). This analysis supports the conclusion that the genome-wide splicing profiles for AML are reproducible.
Aberrant RNA splicing patterns and their frequencies in AML patients
Using annotation analysis, we observed three different patterns of splicing in patients with AML: 
transcripts were subjected to Pattern 1 and 2 splicing in various combinations. Thus, complex combinations of splicing events are frequently detected in AML patients.
Gene categories and pathways affected by aberrant splicing in AML
To identify deregulated pathways affected by aberrant splicing events in patients with AML, we performed a functional enrichment analysis using DAVID (the Database for Annotation, Visualization and Integrated Discovery). This enrichment analysis identified a number of signaling pathways with significance P <0.005 affected by aberrant splicing (Table 3 ). In the DFCI cohort we identified 26 signaling pathways affected by splicing events detected in AML patients. Among the most affected pathways in AML are: FLT3, CD13, c-Kit, NOTCH, PI3K and MAPK signaling, pathways involved in regulation of cell cycle, apoptosis, cell transformation, and splicing (Table 3) .
Similar results were obtained from the analyses of significantly spliced genes in the UHN cohort.
We detected 14 pathways affected by aberrant splicing in the UHN cohort, 12 of which were also detected in the DFCI cohort (Table 3) . Also, for both cohorts for any given signaling pathway, this analysis identified multiple genes that were differentially spliced in AML as compared to NDs (Data not shown). These findings suggest that the effects of AML-specific splicing on signaling networks are widespread and that the splicing mechanism itself is compromised in AML.
Validation of genome-wide splicing studies in AML patients
In order to demonstrate that the exon array data accurately detected transcripts with altered splicing, validation studies were performed on the CD13 gene encoding a myeloid cell surface protein. The CD13 transcripts are among those most often mis-spliced in both patient cohorts that were studied on the exon arrays. 
Evaluation splicing patters of CD13
cDNA representing CD13 transcripts was amplified by RT-PCR, separated by agarose gel electrophoresis, and then cloned and sequenced (Figure 2a-b) . The analysis identified four CD13 splice variant transcripts: CD13Va, CD13Vb, CD13Vc and CD13Vd (Figure 2b) . These CD13 novel splice variant transcripts were not detected in normal CD34+ cells, PB monocytes, or neutrophils (Figure 2a) . Sequence alignment analyses showed that CD13 splice variants are results of exon skipping, partial deletion of an exon and/or partial retention of an intron (Figure 2b) .
Alignment followed by bioinformatic analysis showed that some of these splicing events did not cause any frame shifts (CD13Vd), while other combinations of aberrant splicing led to frameshifted transcripts (e.g CD13Va, CD13Vb and CD13Vc). All the CD13 splice variant transcripts retained their original start codons and conserved signal sequences. Also, alignment analysis showed that exons affected by aberrant splicing events mapped to extracellular domains of the CD13 protein sequences (data not shown). We also evaluated the expression consistency of novel splice variant transcripts over the course of disease in individual AML patients (Figure 3b-d) . CD13-FL and their splice variant transcript expressions were examined in paired samples of 14 patients; samples were taken at diagnosis and remission (3 patients), over the course of refractory disease (4 patients) or diagnosis and relapse (7 patients). A total of 29 samples were collected. This analysis showed specific expression patterns and levels of the novel splice variants at different time points during disease development (Figure   3b-d) . At diagnosis, the majority (>80%) of patients expressed CD13 splice variants in various combinations; at remission, expression frequencies of these splice variants were decreased; and at relapse, expression of all splice variants was dramatically increased at which point each patient expressed two of more CD13 variants in various combinations (Figure 3c-d) . Similarly, in a group of patients with persistent AML, novel splice variant expression frequencies remained constantly high (Figure 3c ).
CD13 splice variant proteins

Discussion
Based on genome-wide AS analyses of AML patients and NDs, in this manuscript we report the presence of widespread splicing changes in AML patients compared to NDs. These splicing events were considered aberrant and specific to AML, because they were not detected in CD34+ bone marrow cells, monocytes, or neutrophils from NDs. Thus, these events may provide potential markers for leukemic stem cells.
Since these AML-specific splicing abnormalities were found not only in the coding region, but also in the 5'-and 3'-untranslated regions (UTR) of the AML transcriptome, we argue that such widespread aberrant splicing in AML leads to altered expression of the genes, which may be necessary to modulate epigenetic regulatory "circuits" in this disease. Those aberrant splicing events that occur in the 3'UTR of the AML transcriptome will compromise miRNA-dependent gene regulation, whereas splicing events in the 5'UTR will change the composition of translational regulatory elements, which in turn can alter protein expression. Furthermore, aberrant splicing events in the coding regions will modulate a core part of the AML proteome and generate altered proteins. Some of these proteins might act in a dominant negative manner and compromise normal functions of their wild type counterparts. Similar effects have been reported for MDM2, p53, CD44, STAT3 and other genes (32-36).
Similar to our findings, several related studies have reported widespread defects in AS in different types of cancer, including lung, breast, colon, prostate, and brain using the Affymetrix Human Exon 1.0ST Arrays (37) (38) (39) (40) . This well-adopted platform appears to be more useful than direct highthroughput sequencing using RNA-Seq when limited amounts of tissue are available from patients.
Exon array analysis requires only 50 ng of total RNA whereas RNA-Seq requires 1.5 ug RNA(41).
Also, even though the dynamic range of RNA-Seq analysis is unparalleled, evaluation of the technical reproducibility of the exon array and RNA-Seq platforms showed that the coefficient of variation for the microarray is lower than that of RNA-Seq (41, 42). Furthermore, human exon array analysis tools are well standardized, short analysis times are achieved, and few computational resources are required as compared to RNA-seq; thus use of exon arrays for screening large patient cohorts can be more practical. In addition to identifying novel transcripts, RNA-Seq analysis detects single nucleotide genetic variants in screened samples, which is one of the powerful options of this technology; however, the tools for RNA-Seq data analysis are not fully mature and capturing low abundance transcripts is compromised. Thus, microarrays remain a more useful and accurate 
platform for screening large number of patient samples at this point. More details regarding the pros and cons of microarrays and RNA-Seq have been reported recently (41, 42) . The combined use of both technologies holds much promise to identify genome-wide disease related aberrations.
Our study identified that a majority of the transcripts in AML patients are subject to complex splicing events that include partial exon deletions and partial or complete intron retentions in various combinations. These events are detected on single transcripts and are highly recurrent as demonstrated for the CD13 gene in this manuscript, and for the NOTCH2 and FLT3 genes elsewhere, in 193 AML patients. Similar patterns of aberrant splicing have been observed for oncogenes or genes associated with other malignant phenotypes; in these malignancies, splicing alterations produced novel transcripts encoding functional proteins (17, 19, 31, 43, 44) .
Our results suggests that splicing is a global phenomenon in AML, raising the question as to whether modulated splicing in AML is a sporadic process or is organized/associated with the disease status. In longitudinal studies carried on limited number of AML patient samples we noted significant differences with respect to expression frequencies of the splice variants at different time points of disease progression. Our findings suggest that splicing events are increased at diagnosis and relapse and "normalized" during remission. Extended studies are in progress to confirm our findings, which well allow us identification novel biomarker reflecting disease status, and consequently identify selective druggable targets.
Finally, the splicing aberrations we report in this manuscript might alter mechanisms of splicing via modulation of splicing factors and/or proteins. In this context, it is noteworthy that we identified The CD13Va and CD13-Vb splice variants are the result of complete deletions of exon 4 (140bp) or exons 4 (140bp) and 6 (155bp), respectively, while CD13Vc is a result of a partial deletion of exon 4 (44bp) and a complete deletion of exon 6 (155bp). The CD13-Vd splice variant transcript is result of activation of a cryptic 3' splicing site on intron 4. This splicing aberration causes the partial retention of intron 4 (132bps). The splicing event does not lead to a frameshift, and the native stop codon is retained. However, as a result of these aberrations 140bp is spliced out from CD13Va, 295bp from CD13Vb and 199bp from CD13Vc transcripts. Thus, all these transcripts are subjected to frameshift. 
